Compare FLNA & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNA | LFT |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 35.8M |
| IPO Year | 2000 | 2012 |
| Metric | FLNA | LFT |
|---|---|---|
| Price | $0.45 | $4.05 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 319.1K | 19.4K |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | ★ 29.63% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,119,000.00 | N/A |
| Revenue This Year | N/A | $168.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $3.85 |
| 52 Week High | $2.03 | $69.35 |
| Indicator | FLNA | LFT |
|---|---|---|
| Relative Strength Index (RSI) | 34.15 | 43.92 |
| Support Level | N/A | N/A |
| Resistance Level | $1.05 | $5.83 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | -0.01 | 0.19 |
| Stochastic Oscillator | 8.07 | 23.33 |
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.